Adma Biologics (ADMA) Retained Earnings (2011 - 2025)

Adma Biologics' Retained Earnings history runs 14 years deep, the most recent figure standing at -$161.7 million for Q4 2025.

• Quarterly Retained Earnings rose 47.61% year-over-year to -$161.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$161.7 million (up 47.61% YoY) and the FY2025 annual result came in at -$161.7 million, up 47.61% from the prior year.
• Retained Earnings was -$161.7 million for Q4 2025 at Adma Biologics, down from $665.4 million in the prior quarter.
• Across five years, Retained Earnings topped out at $665.4 million in Q3 2025 and bottomed at -$506.3 million in Q4 2023.
• A 5-year average of $252.7 million and a median of $558.6 million in 2021 frame the typical range for Retained Earnings.
• Peak annual rise in Retained Earnings reached 249.62% in 2022, while the deepest fall reached 193.49% in 2022.
• Adma Biologics' Retained Earnings stood at $553.3 million in 2021, then tumbled by 186.4% to -$478.0 million in 2022, then slipped by 5.91% to -$506.3 million in 2023, then soared by 39.05% to -$308.6 million in 2024, then surged by 47.61% to -$161.7 million in 2025.
• Business Quant data shows ADMA's Retained Earnings at -$161.7 million in Q4 2025, $665.4 million in Q3 2025, and $660.9 million in Q2 2025.